Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus

2002 ◽  
Vol 18 (S3) ◽  
pp. S77-S81 ◽  
Author(s):  
Hannele Yki-J�rvinen
2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Yoshiro Fushimi ◽  
Atsushi Obata ◽  
Junpei Sanada ◽  
Yuichiro Iwamoto ◽  
Akiko Mashiko ◽  
...  

Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients’ adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c (ΔHbA1c) was strongly related to HbA1c levels at baseline. As expected, serum glucagon level was increased after starting the combination therapy. Interestingly, however, the change of glucagon levels (Δglucagon) was not related to HbA1c levels at baseline, ΔHbA1c, and other parameters, which indicated that the increase of glucagon did not clinically affect the effectiveness of combination therapy. In addition, the change of urinary albumin excretion (ΔUAE) was negatively correlated with systolic blood pressure and HbA1c levels at baseline and positively correlated with the change of systolic blood pressure (ΔsBP) in univariate analysis. Furthermore, in multivariate analysis, only ΔsBP was the independent factor associated with ΔUAE. Taken together, canagliflozin as add-on therapy to teneligliptin improves glycemic control in a Δglucagon-independent manner and reduces UAE in a ΔsBP-dependent manner in Japanese subjects with T2DM.


Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3152
Author(s):  
Saman Agad Hashim ◽  
Mohd Yusof Barakatun-Nisak ◽  
Hazizi Abu Saad ◽  
Suriani Ismail ◽  
Osama Hamdy ◽  
...  

While the role of medical and nutrition factors on glycemic control among adults with type 2 diabetes mellitus (T2DM) has been well-established, the association between health literacy (H.L.) and glycemic control is inconsistent. This study aims to determine the association of H.L. and nutritional status assessments with glycemic control in adults with type 2 diabetes mellitus. A total of 280 T2DM respondents (mean (SD) age = 49.7 (10.3) years, Glycated hemoglobin (HbA1c) = 9.9 (2.6) %, and Body Mass Index = 32.7 (15.1) kg/m2) were included in this study. A short-form Test of Functional Health Literacy in Adults (S-TOFHLA) assessed the H.L. levels. Nutritional status assessments included client history, glycemic control, anthropometric, and biochemical data. The mean (S.D.) H.L. score was 45.7 (24.6), with 56% of the respondents had inadequate H.L. Inadequate H.L. was more common among those females; housewives, low education, received oral antidiabetic therapy, and shorter diabetes duration. Respondents with inadequate H.L. were significantly older and had higher HbA1c than those with marginal and adequate H.L. Meanwhile, respondents with inadequate and marginal H.L. levels had significantly higher total cholesterol, LDL-cholesterol, and systolic blood pressure than the respondents with adequate H.L. Low H.L. scores, self-employment status, received dual antidiabetic therapy (insulin with oral agents), received insulin alone, and had higher fasting blood glucose explained about 21% of the total variation in HbA1c (adjusted R2 = 0.21; p < 0.001). Respondents with inadequate H.L. had poor glycemic control. The H.L. scores, together with nutritional status assessments, were the factors that predicted poor glycemic control among adults with T2DM.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 137-LB ◽  
Author(s):  
NEHA KARAJGIKAR ◽  
KARLA B. DETOYA ◽  
JANICE N. BEATTIE ◽  
STACEY J. LUTZ-MCCAIN ◽  
MONIQUE Y. BOUDREAUX-KELLY ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 90-LB
Author(s):  
SANJAY K. BAJPAI ◽  
RADHIKA NAIR ◽  
TICH CHANGAMIRE ◽  
RICHARD SHEER ◽  
QIANQIAN WANG ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document